Mumbai, June 25 -- Dyrupeg contains the active substance pegfilgrastim and is a biological medicine. It is a 'biosimilar medicine'; this means that Dyrupeg is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the area of the regulatory agency.

Dyrupeg is intended for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Earlier in April 2025, Dyrupeg received marketing authorization in the European Union from the European Commission (EC).

This is CuraTeQ's third biosimilar to be approved by MHRA after the...